
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc's positive outlook is bolstered by the anticipated approval of PRGN-2012, a promising therapy for recurrent respiratory papillomatosis (RRP), which is expected to enhance awareness and improve diagnostic accuracy. The therapy's demonstrated efficacy, particularly its significant reduction in the need for surgeries among patients, supports its acceptance by specialists within the medical community. Additionally, there is a strong confidence in the likelihood of PRGN-2012 receiving regulatory approval by the upcoming PDUFA date of August 27, 2025, further underscoring the stock's favorable prospects.
Bears say
Precigen Inc. faces significant challenges in maintaining or growing its reported sales due to unfavorable broader market conditions and competitive dynamics, which raises concerns about the sustainability of its revenue. The company has a longstanding history of financial losses and lacks a proven track record of consistent profitability, further complicating its financial health. Additionally, the presence of balance sheet risks could hinder the company's ability to secure future funding or execute its business strategy effectively.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares